Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company primarily focused on the development and commercialization of biopharmaceutical products. Co. is developing medications for central nervous system disorders with a focus on abuse-deterrent medications. Co.'s primary investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall®) for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. ADAIR is designed to deter attempts to crush and snort and to provide barriers to injection while still providing the therapeutic benefit when taken orally. The VLON average annual return since 2021 is shown above.
The Average Annual Return on the VLON average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether VLON average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VLON average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|